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I. Introduction
With this issue, we are introducing a revised
format for our description of surveillance data,
which focuses on presentation of data with figure
and tables and limited text. We invite readers to
send us comments (see Preface for address). A copy
of this report is available on the CDC Internet site at
http://www.cdc.gov/hepatitis.
This report summarizes surveillance data
collected during 1994-1995 for acute viral hepatitis.
With a total of 46,963 cases reported to CDC in 1995,
acute viral hepatitis was exceeded only by AIDS
(71,547 cases), chlamydia (477,638 cases), gonorrhea
(392,848 cases), and syphilis (68,953 cases) among
reportable diseases in the United States. After
declining from 1989-1993, the overall case count has
increased from 1994-1995 as a result of a cyclic
increase in hepatitis A. In 1995, a total of 31,582
cases of hepatitis A were reported, which was the
highest yearly total since 1989. Hepatitis B has
declined steadily since 1985.
The objective of national surveillance of acute
viral hepatitis is to provide serologic, demographic,
and epidemiologic information that will aid in
formulating strategies and policies for the preven-
tion and control of these diseases. The hepatitis
surveillance report interprets and disseminates this
information, presents new developments in the
field, and clarifies issues related to viral hepatitis.
Nationwide information on hepatitis is obtained
by two surveillance systems. In one, incidence data
are collected from cases reported to the CDC
National Notifiable Diseases Surveillance System
(NNDSS) by each state and territory. The etiologic
classification is made by physician diagnosis; confir-
mation by serologic testing is not required. The
number of cases and date reported of hepatitis A,
hepatitis B and hepatitis C/non-A, non-B appear in
the Morbidity and Mortality Weekly Report (MMWR)
and the MMWR Annual Summary of Notifiable
Diseases, and are summarized in this report as well.
In the other system, clinical, serologic and
epidemiologic data pertaining to risk factors for
disease acquisition are obtained from the Viral
Hepatitis Surveillance Program (VHSP), a separate
reporting system operated by the Hepatitis Branch,
Division of Viral and Rickettsial Diseases, National
Center for Infectious Diseases, CDC, Atlanta, Geor-
gia. The VHSP obtains its information from the viral
hepatitis case record, a copy of which appears in the
Appendix. This form (CDC 53.1) can be obtained
from the Hepatitis Branch. In addition, in 1991
several states began submitting their case reports via
electronic surveillance through the National Elec-
tronic Telecommunications System for Surveillance
(NETSS). By 1995, 67% of VHSP cases were submit-
ted electronically. For states interested in using
NETSS to report hepatitis case investigations (core
data plus extended record for serologic and risk
factor data), the Hepatitis Branch and CDC’s Epide-
miology Program Office will provide technical
support.
A third surveillance system referenced in this
report is the Sentinel Counties Study of Acute Viral
Hepatitis, a more intensive study of viral hepatitis in
six counties representative of the United States as a
whole. This surveillance system has provided
nationally representative data on acute viral hepati-
tis since 1982, and has been a resource for detecting
emerging infections and performing more in-depth
studies. Data from the Sentinel Counties have been
included for comparison with the other surveillance
systems in this issue.
Surveillance data such as those reported here are
dependent on the cooperation of state and local
health departments, public health practitioners, and
medical care persons reporting the diseases from
their hospitals, clinics, and offices. In 1995, some 20
states reported VHSP data on at least 60% of their
total cases.
CDC’s ability to accurately analyze and interpret
nationwide trends and patterns, identify high-risk
groups, and determine mechanisms of transmission
for each type of hepatitis depends on the coopera-
tion of the state and local health departments in
reporting laboratory and epidemiologic data to the
VHSP. Key to these tasks is the accurate determina-
tion of the specific agent causing the viral hepatitis.
Five distinct agents are responsible for viral hepati-
tis diseases worldwide; four have been identified as
endemic in the United States: hepatitis types A, B, C,
and D. The last type, Delta hepatitis, is not a report-
able disease in the United States, and occurs only as
a coinfection or superinfection with hepatitis B
virus.
Hepatitis E virus (HEV) is the major etiologic
agent of enterically transmitted, non-A, non-B hepa-
titis worldwide. Hepatitis E is most commonly
recognized to occur in outbreaks associated with
fecally contaminated drinking water. In many areas
in which hepatitis E outbreaks have been reported,
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HEV infection accounts for a substantial proportion
of acute sporadic hepatitis in both children and
adults. Virtually all cases of acute hepatitis E in the
United States have been reported among travelers
returning from high HEV-endemic areas. Recently,
however, several cases of clinical acute hepatitis E
have been reported among persons with no history
of travel outside the United States.
The hepatitis G virus (HGV) and TT virus (TTV)
are agents recently identified in patients with viral
hepatitis. However, studies conducted to date have
shown no association between these agents and
acute or chronic hepatitis.
We thank those who have been actively contrib-
uting to the viral hepatitis surveillance program
and encourage others to participate.
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II. Issues and Answers
What diagnostic tests for hepatitis E virus infection are available?
In the United States, hepatitis E is rare, and most
reported cases have been associated with travel to
HEV-endemic regions (1, 2). However, several cases of
acute hepatitis E have been reported among persons
with no recent history of travel outside the United
States (3, 4). In addition, a new virus has recently been
discovered in pigs in the United States that is closely
related to human HEV isolates, which raises the possi-
bility of zoonotic transmission of HEV (5).
HEV infection should be considered in patients
with signs and symptoms of acute viral hepatitis
who are negative for serologic markers of acute
hepatitis A (immunoglobulin M [IgM] antibody to
hepatitis A virus), acute hepatitis B (IgM antibody to
hepatitis B core antigen), and hepatitis C (antibody
to hepatitis C virus). No serologic tests for hepatitis
E are commercially available in the United States,
but serologic assays that detect IgM-and IgG-specific
antibody to HEV and polymerase chain reaction
tests that detect HEV RNA are available in research
laboratories. Health-care professionals who need
information on serologic testing of persons with
evidence of acute non-ABC hepatitis may contact
CDC’s Hepatitis Branch, Division of Viral and
Rickettsial Diseases, National Centers for Infectious
Diseases, telephone (404) 371-5910.
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What diagnostic tests for agents of acute non-A-E hepatitis are available?
Recently two isolates of a new virus designated
hepatitis G virus (HGV) or hepatitis GB virus C
(GBV-C) were identified in patients with viral hepa-
titis (6,7). In addition, a new virus named TT virus
(TTV) was identified in patients with
post-transfusion hepatitis and in patients with
chronic liver disease of unknown etiology (8). Both
of these viruses appear to be transmitted by transfu-
sion; however, studies conducted to date have not
implicated either of these viruses as an agent of
acute or chronic hepatitis (8,9). No tests for HGV
(GBV-C) or TTV infection are commercially avail-
able in the United States, but polymerase chain reac-
tion tests that detect nucleic acid of these viruses are
available in research laboratories. Until further stud-
ies demonstrate that these, or other viruses, are a
cause of acute or chronic viral hepatitis and suitable
diagnostic tests are developed, testing for these
agents will not be routinely performed in the CDC’s
Hepatitis Branch Laboratory.
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Internet Access to CDC Viral Hepatitis Information
In recent years, public health practitioners,
epidemiologists and state and local health depart-
ment personnel have taken advantage of the Internet
to create easy and timely access to information criti-
cal to the public health, including surveillance data
on reported diseases. CDC provides Internet access
to public documents, tables, and data sets for down-
loading via the CDC home page
(http://www.cdc.gov) and links to CDC
program-specific sites. The following provides a
brief description of the information accessible
through the Hepatitis Branch Internet site and the
current Internet browser address. Check Internet
sites frequently; new information is posted on a
regular basis.
Hepatitis Branch Home Page (http://www.cdc.gov/hepatitis)
The Hepatitis Branch home page provides recent
documents, brochures, announcements, and slide
sets, as well as the toll-free number for accessing
information on viral hepatitis . Links to information
specific to each type of viral hepatitis are provided,
including fact sheets, frequently asked questions,
disease burden details, and recommendations
(usually published in the MMWR).
To provide access to documents directly, the
Home Page provides a link titled “Resource Center.”
Clicking on this link will open a page listing surveil-
lance reports, slide sets, MMWR articles containing
recommendations and guidelines, brochures, and
other items. For those looking for additional infor-
mation on viral hepatitis, links to other sites includ-
ing —the National Digestive Diseases Information
Clearinghouse, the National Institutes of Health and
non-governmental organizations— are provided on
this page.
If you have any questions or comments on the
Hepatitis Branch Internet site, or have suggestions
for additional information or links, please send them
to Chief, Viral Hepatitis Surveillance, Hepatitis
Branch, CDC, 1600 Clifton Road, Mail Stop G37,
Atlanta, GA 30333
IV. National Surveillance for Acute
Viral Hepatitis through 1995
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Types of Hepatitis
Hepatitis A Hepatitis B Hepatitis C/NANB* Unspecified Total
Year No. Rate** No. Rate No. Rate No. Rate No. Rate
1966 32,859 16.77 1,497 0.79 *** *** † † 34,356 17.56
1967 38,909 19.67 2,458 1.28 *** *** † † 41,367 20.95
1968 45,893 22.96 4,829 2.49 *** *** † † 50,722 25.45
1969 48,416 23.98 5,909 3.02 *** *** † † 54,325 27.00
1970 56,797 27.87 8,310 4.08 *** *** † † 65,107 31.95
1971 59,606 28.90 9,556 4.74 *** *** † † 69,162 33.64
1972 54,074 25.97 9,402 4.52 *** *** † † 63,476 30.49
1973 50,749 24.18 8,451 4.03 *** *** † † 59,200 28.21
1974 40,358 19.54 10,631 5.15 *** *** 8,351 3.95 59,340 28.07
1975 35,855 16.82 13,121 6.30 *** *** 7,158 3.44 56,134 26.34
1976 33,288 15.51 14,973 7.14 *** *** 7,488 3.57 55,749 25.97
1977 31,153 14.40 16,831 7.78 *** *** 8,639 3.99 56,623 26.17
1978 29,500 13.53 15,016 6.89 *** *** 8,776 4.02 53,292 24.44
1979 30,407 13.82 15,452 7.02 *** *** 10,524 4.79 56,393 25.62
1980 29,087 12.84 19,015 8.39 *** *** 11,894 5.25 59,996 26.49
1981 25,802 11.25 21,152 9.22 *** *** 10,975 4.79 57,929 25.26
1982 23,403 10.11 22,177 9.58 2,629 1.14 8,564 3.40 56,773 24.52
1983 21,532 9.20 24,318 10.39 3,470 1.48 7,149 3.05 56,469 24.12
1984 22,040 9.33 26,115 11.06 3,871 1.64 5,531 2.34 57,557 24.37
1985§ 23,257 10.04 26,654 11.51 4,192 1.81 5,530 2.39 59,633 25.76
1986§ 23,430 10.02 26,107 11.17 3,634 1.55 3,940 1.69 57,111 24.43
1987 25,280 10.39 25,916 10.65 2,999 1.23 3,102 1.27 57,297 23.54
1988 28,507 11.59 23,177 9.42 2,619 1.07 2,470 1.00 56,773 23.10
1989 35,821 14.43 23,419 9.43 2,529 1.02 2,306 0.93 64,075 25.81
1990 31,441 12.64 21,102 8.48 2,553 1.03 1,671 0.67 56,767 22.81
1991 24,378 9.67 18,003 7.14 3,582 1.42 1,260 0.50 47,223 18.73
1992 23,112 9.06 16,126 6.32 6,010 2.36 884 0.35 46,132 18.09
1993 24,238 9.39 13,361 5.18 4,786 1.86 627 0.24 43,012 16.68
1994 26,796 10.29 12,517 4.81 4,470 1.78 444 0.17 44,227 17.05
1995 31,582 12.02 10,805 4.16 4,576 1.76 ‡ ‡ 46,963 18.00
* Number and rates shown for hepatitis C/Non-A, non-B hepatitis are unreliable-see note p. xx of this report.
** Rate per 100,000 population
*** Not reported until 1982
† Not reported until 1974
§ Excludes cases from New York City; data not available for 1985 or 1986.
‡ No longer reported as of 1995.
Source: National Notifiable Diseases Surveillance System
Table IV-1. Reported Cases of Viral Hepatitis, by Type and Year, United States, 1966-1995
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Hepatitis A
Hepatitis A incidence varies cyclically, with an interepidemic period of 7 to 10 years. The most recent increase, which












































Figure IV-1. Hepatitis A by Year, United States, 1952-1995
Source: National Notifiable Diseases Surveillance System
The incidence of hepatitis A varies regionally: rates in
the West are 2-5 times higher than in the rest of the
nation. The underlying reason for these differences has
not been determined; the regions do not differ substan-
tially with respect to the distribution of known risk
factors. However, higher incidence rates in the West do
correlate with demographic factors (e.g., counties with
10% or more of the population classified as American
Indian had average rates 3.5 times higher than counties
where less than 10% of the population are American Indi-
ans; counties with 15% or more of the population classi-
fied as Hispanic had average rates 2.1 times higher than
counties with less than 15% classified Hispanic).
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Figure IV-2. Reported Cases of Hepatitis A, by Region, United States, 1975 - 1995
Source: National Notifiable Diseases Surveillance System
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IV. National Surveillance for Acute Viral Hepatitis through 1995
States in the West have a higher proportion of
counties with moderate-to-high hepatitis A rates.
Children living in states or communities including
counties or groups of counties that have hepatitis A
rates consistently higher than the national average
should be vaccinated. In states where the average
annual hepatitis A rate over the past 10 years was at
least 20/100,000 (i.e., approximately twice the
national average), routine vaccination of children is
recommended; in addition, it should be considered
in states where the average annual rate for the same
period while less than 20/100,000 was as at least
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Figure IV-3. Reported Cases of Hepatitis A by County, United States, 1995
Source: National Notifiable Diseases Surveillance System
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IV. National Surveillance for Acute Viral Hepatitis through 1995
The incidence rates of acute hepatitis A are substantially higher in persons less than 40 years of age than for older
age-groups. However, the incidence rates for different age-groups among persons under 40 are similar: no single






























Figure IV-4. Reported Cases of Hepatitis A by Age, United States, 1983-1995
Source: National Notifiable Diseases Surveillance System
Clinical Characteristics
The overall rate of hospitalization of patients with hepatitis A was similar to that of previous years (18.5% to 20.4% for
1990-1993) and the overall case-fatality rate was less than 1%. The rate of hospitalization and the case-fatality rate for
hepatitis A patients both increase with increasing age.
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IV. National Surveillance for Acute Viral Hepatitis through 1995










Jaundice 84.8 84.5 86.8 80.4
Hospitalized for hepatitis 17.9 8.9 18.7 29.5
Death as a result of hepatitis 0.8 0.1 0.8 1.7
1995 N=14,229 N=3,426 N=7,887 N=2,762
Jaundice 83.6 80.6 86.3 79.6
Hospitalized for hepatitis 19.4 9.3 20.3 28.8
Death as a result of hepatitis 0.3 0.1 0.3 0.8
Table IV-2. Clinical Characteristics of Patients Reported with Hepatitis A, by Age-Group, United States,
1994-1995
* Percentages exclude patients with missing data for age (2% of total), jaundice (14%-17% of total), hospitalization
(15%-16% of total), and death (19% of total).
Source: Viral Hepatitis Surveillance Program, CDC.
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Demographic Characteristics
As in previous years,
 children and adolescents (<20 years of age) accounted for approximately one-third cases in both
1994 and 1995,
 a higher proportion of cases occurred among males than among females, and





CHARACTERISTIC No. %* No. %*
Age (Years)
<5 792 6.8 724 5.1
5-9 1,754 15.1 1,596 11.3
10-14 1,100 9.4 1,106 7.8
15-19 918 7.9 1,146 8.1
20-29 2,526 21.7 3,688 26.1
30-39 2,175 18.7 3,053 21.6
40-49 1,136 9.7 1,477 10.5
50-59 506 4.3 605 4.3
60+ 745 6.4 715 5.1
Sex
Male 6,494 56.0 7,975 56.7
Female 5,093 44.0 6,078 43.3
Race/Ethnicity
White, non-Hispanic 6,786 62.3 8,736 68.6
Black, non-Hispanic 1,026 9.4 1,450 11.4
Hispanic 1,378 12.7 1,309 10.3
American Indian or Alaskan Native 1,477 13.6 1,061 8.3
Asian or Pacific Islander 217 2.0 180 1.4
Table IV-3. Reported Cases of Hepatitis A by Age, Sex, and Race/Ethnicity, United States, 1994-95
*A total of 11,741 and 14,229 cases of hepatitis A were reported to VHSP in 1994 and 1995 respectively. Percentages in this table
exclude patients with missing data.
Source: Viral Hepatitis Surveillance Program, CDC.
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Risk factor analysis
Among cases for whom a risk factor was identi-
fied, contact with another person with hepatitis A
was overall the most frequently identified risk
factor. Among cases occurring in persons less than
15 years of age, attending day-care was the most
frequently identified risk factor, and for cases in
persons 15-39 years of age, contact with a day-care
child or employee was the 2nd most commonly iden-
tified risk factor. However, information is not
routinely collected to determine whether the
day-care contact is infected with hepatitis A virus,
and although day-care centers might be the source
of outbreaks of hepatitis A within some communi-
ties, disease within day-care centers more commonly
reflects extended transmission in the community.
International travel was reported for 7% of hepa-
titis A cases in 1995. Of these travel-related cases,
51% were associated with trips to South and Central
America and 11% to travel in Asia and the South
Pacific. Some 70% of these travel-related hepatitis
A cases were associated with trips of more than 7
days, 15% were associated with trips of 4-7 days,
and 15% were associated with trips of <3 days.
Among cases associated with travel of less than 4
days’ duration, 90% involved travel to
South/Central America.
Nearly one-half of hepatitis A case-patients in
both 1994 and 1995 reported no known risk factor.
However, evidence from epidemiologic studies indi-
cates that asymptomatic infections, particularly in
children, play an important role as unrecognized
sources of infection.
Percentage of Patients by Age (years)**
1994
Total <1-14 15-39 40
N = 11,741 N = 3,638 N = 5,610 N = 2,386
Child/employee in day-care center 7.8 18.2 3.3 2.4
Contact of day-care child/employee 8.3 7.3 10.2 5.1
Sexual contact with hepatitis A patient 1.8 0.0 2.8 2.1
Household contact of hepatitis A patient 7.8 11.3 6.7 5.0
Other contact of hepatitis A patient 10.6 13.5 10.7 6.0
Suspected food- or waterborne outbreak 2.6 1.7 2.7 4.1
International travel 7.3 6.0 7.6 8.4
Homosexual activity 4.7 0.5 8.3 3.3
Injection drug use 3.2 0.1 7.3 2.5
Unknown 45.9 41.4 40.4 59.9
1995 N=14,229 N=3,425 N=7,885 N=2,797
Child/employee in day-care center 6.1 17.1 2.2 3.0
Contact of day-care child/employee 8.7 8.2 9.9 6.1
Sexual contact with hepatitis A patient 2.4 0.1 3.5 2.1
Household contact of hepatitis A patient 8.8 13.8 7.8 5.6
Other contact of hepatitis A patient 11.3 10.9 12.7 8.0
Suspected food- or waterborne outbreak 2.2 1.3 2.5 2.5
International travel 6.8 7.7 6.0 7.9
Homosexual activity 5.1 0.8 6.6 5.3
Injection drug use 5.0 0.1 7.8 3.4
Unknown 43.6 40.1 41.0 56.1
* Mutually exclusive groups, in decreasing order of most probable source.
**A total of 11,741 and 14,229 cases of hepatitis A were reported to VHSP in 1994 and 1995 respectively. Percentages in this table
exclude patients with missing risk factor data.
Table IV-4. Epidemiologic Characteristics* during the 2 to 6 Weeks Prior to Illness of Patients
Reported with Hepatitis A, by Age-Group, United States, 1994-1995
Source: Viral Hepatitis Surveillance Program, CDC.
Hepatitis Surveillance 13
IV. National Surveillance for Acute Viral Hepatitis through 1995
Cyclical increases in hepatitis A in the 1980s and
1990s have been primarily associated with an
increase in cases among persons with personal
contact with another person with hepatitis A, and an
increase in cases associated with child day-care. The
increase in hepatitis A incidence from 1994-1995 has
been associated with an increase in cases among
men who have sex with men, and among injecting
drug users with outbreaks among these groups
reported in several states. The number of cases asso-
ciated with common-source outbreaks is relatively
small (<500) and remained stable during 1983-1995.
Similar trends in risk factors for hepatitis A were
found in data from the Sentinel Countries Study of
Viral Hepatitis. However, in contrast to the VHSP
data, Sentinel Counties data show no appreciable
increase in day-care-associated or foreign






























Figure IV-5. Trends in Selected Risk Factors for Patients Reported with Hepatitis A, by Mutually
Exclusive Groups, United States, 1983-1995
Source: Viral Hepatitis Surveillance Program, CDC.
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Hepatitis B
Hepatitis B incidence increased from 1966 through 1985. This increase was at least partially due to increased use of
serologic testing and also to erroneous reporting of chronically infected persons. From 1985 to 1995, the incidence of

































Figure IV-6. Hepatitis B by Year, United States, 1966-1995
Source: National Notifiable Diseases Surveillance System
In recent years, incidence rates across the United States have declined. They are now similar in all regions.
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Figure IV-7. Reported Cases of Hepatitis B, by Region, United States, 1975-1995
Source: National Notifiable Diseases Surveillance System
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IV. National Surveillance for Acute Viral Hepatitis through 1995








< 4.0 4.0 - < 8.0RATE per 100,000
Figure IV-8. Reported Incidence of Hepatitis B Per 100,000 Population, United States, 1995
Source: National Notifiable Diseases Surveillance System
Hepatitis Surveillance 17
IV. National Surveillance for Acute Viral Hepatitis through 1995
Incidence rates have declined in all age-groups from
1989-1995, but the most dramatic occurred in those 15-39
years of age, in whom the number of reported cases has
decreased by more than 50%. The decline in the number
of cases occurring in this age-group accounted for most of
the decline in overall incidence and is primarily attributed
to unexplained reductions in incidence among injection
drug users. The extent to which routine vaccination of
health-care workers has affected the overall declining
incidence of acute hepatitis B among persons 15 to 39













Figure IV-9. Reported Cases of Hepatitis B, by Age, United States, 1983-1995
Source: National Notifiable Diseases Surveillance System
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Demographic Characteristics
The demographic profile of hepatitis B cases in 1994 and 1995 was similar to that of previous years.
 60% of reported cases occurred in persons 20-39 years of age.
 The male:female case ratio was 1.6:1
 Non-Hispanic blacks accounted for a higher percentage of total hepatitis B cases compared to





CHARACTERISTIC No. %* No. %
Age (Years)
<5 22 0.5 16 0.3
5-9 38 0.9 34 0.7
10-14 55 1.3 60 1.2
15-19 314 7.1 356 7.3
20-29 1,403 31.9 1,427 29.2
30-39 1,326 30.2 1,550 31.7
40-49 691 15.7 796 16.3
50-59 278 6.3 344 7.0
60+ 271 6.2 302 6.2
Sex
Male 2,641 60.3 2,999 61.4
Female 1,737 39.7 1,884 38.6
Race/Ethnicity
White, non-Hispanic 2,391 58.1 2,361 53.6
Black, non-Hispanic 1,263 30.7 1,453 33.0
Hispanic 295 7.2 380 8.6
American Indian or Alaskan Native 51 1.2 58 1.3
Asian or Pacific Islander 114 2.8 153 3.5
Table IV-5. Distribution of Hepatitis B by Age, Sex, and Race/Ethnicity, United States, 1994-95.
* A total of 4,426 and 4,929 cases of hepatitis B were reported to VHSP in 1994 and 1995 respectively; however, this table
excludes patients with missing risk factor data.
Source: Viral Hepatitis Surveillance Program, CDC.
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Clinical Characteristics
The clinical profile of cases of acute hepatitis B reported in 1994 and 1995 was similar to that reported in
previous years
 Jaundice was reported in approximately 80% of hepatitis B cases.
 Overall, approximately 28% of cases were hospitalized in 1995, a decrease from 30% in 1994.
Hospitalization rates increased with increasing age.
 Death as a result of acute hepatitis B was reported in approximately 1% of cases.










Jaundice 82.7 70.7 85.0 78.0
Hospitalized for hepatitis 30.1 29.7 27.7 36.2
Death as a result of hepatitis 1.4 1.0 0.8 2.9
1995 N=4,885 N=110 N=3,333 N=1,442
Jaundice 77.7 69.2 81.9 68.3
Hospitalized for hepatitis 27.9 23.3 24.7 35.8
Death as a result of hepatitis 1.1 0.0 0.8 1.9
Table IV-6. Clinical Characteristics of Patients Reported with Hepatitis B, by Age-Group, United States,
1994-1995
* A total of 4,426 and 4,929 cases of hepatitis B were reported to VHSP in 1994 and 1995 respectively; however, percentages in
this table exclude patients with missing data for age (1% of total), jaundice (10%-22% of total), hospitalization (9%-19% of total),
and death (10%-18% of total).
Source: Viral Hepatitis Surveillance Program, CDC.
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Risk factors
Injection drug use was the predominant known
risk factor reported in 1994 and 1995, followed by
sexual exposures. A total of 4%-5% of cases
reported sexual contact with a person known to be
infected with hepatitis B virus. Another 20% of
case-patients are attributed to other sexual expo-
sures, including 10% who report homosexual activ-
ity and 10% who had multiple sexual partners.
Employment in the medical or dental field, blood
transfusions, and dialysis accounted for less than 3%
of cases. The widespread use of hepatitis B vaccine
among health-care workers has reduced their inci-
dence of disease markedly; in 1985, these workers
accounted for 9% of reported cases, compared to
0.8% in 1994-1995.
Although more than one-half of case-patients
reported in 1994 and 1995 denied a recognized expo-
sure, data from the Sentinel Counties study indicate
that most persons who deny a specific exposure




of Patients by Age (Years)
1994
Total <1-14 15-39 40
N = 4,426 N = 115 N = 3,042 N = 1,240
Injection drug use 12.1 4.3 14.1 7.8
Homosexual activity 9.6 6.6 11.3 5.7
Employed in medical/dental field 0.8 6.1 0.8 0.8
Hemodialysis 0.3 0.0 0.3 0.5
Sexual contact of hepatitis B patient 5.0 1.0 5.9 3.2
Household contact with hepatitis B patient 1.5 4.4 1.4 1.5
Other contact with hepatitis B patient 1.1 1.0 1.0 0.8
Multiple sex partners 11.6 2.6 13.8 7.1
Blood transfusion 1.8 1.0 0.6 4.6
Unknown 56.2 73.3 50.7 67.8
1995
Total <1-14 15-39 ≥40
N = 4,929 N = 110 N = 3,333 N = 1,442
Injection drug use 12.9 5.8 15.1 8.4
Homosexual activity 10.7 1.4 12.7 6.7
Employed in medical/dental field 0.6 0.0 0.5 1.1
Hemodialysis 0.3 0.9 0.2 0.6
Sexual contact of hepatitis B patient 4.3 2.7 4.7 3.5
Household contact with hepatitis B patient 1.2 11.8 1.1 0.7
Other contact with hepatitis B patient 1.3 1.8 1.4 1.0
Multiple sex partners 9.5 1.8 11.2 6.1
Blood transfusion 1.6 0.0 0.7 4.0
Unknown 57.5 72.8 52.4 67.6
* Mutually exclusive groups, in decreasing order of most probable source.
†
A total of 4,426 and 4,929 cases of hepatitis B were reported to VHSP in 1994 and 1995, respectively. Percentages above
exclude patients with missing risk factor data.
Table IV-7. Epidemiologic Characteristics* of Patients Reported with Hepatitis B, by Age Group,
United States, 1994-95
Source: Viral Hepatitis Surveillance Program, CDC
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Figure IV-10. Trends in Selected Risk Factors for Males Reported with Hepatitis B, by Mutually































Figure IV-11. Trends in Selected Risk Factors for Females Reported with Hepatitis B, by Mutually
Exclusive Groups, Selected States,* 1983-1995
* Cases from 15 selected states with high reporting levels
Source: Viral Hepatitis Surveillance Program, CDC
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Men
 Among men, the number of cases associated with injection drug use decreased by 85% from 1989 to 1993,
but increased from 1993 to 1995.
 The number of cases associated with male homosexual activity declined by more than 50% from 1983 to
1992, but has increased from 1993 to 1995.
 Cases among men attributable to exposure to an HBV-infected contact remained stable in the early 1990s
after declining in the late 1980s. For these cases, 57% of contacts were sexual and 19% were household
contacts.
 A decline in cases associated with health-care employment that began in the mid-1980s continued through
1992 but has since stabilized.
Women
 The number of cases associated with injecting drug use among women, which declined approximately 70%
from 1989 to 1991, has remained stable from 1993 to 1995.
 Cases among women associated with exposure to an HBV-infected contact and with multiple sexual part-
ners have declined through 1993 but have since plateaued.
 The number of cases associated with medical or dental employment has declined more sharply among
women than among men since 1989.
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Hepatitis C/NANB Hepatitis
The Sentinel Counties Study of Acute Viral Hepatitis,
which has provided the only accurate surveillance data for
monitoring incidence of acute hepatitis C, has shown a
more than 80% decline in incidence from 1989 to 1995
(above). State reporting of hepatitis C cases to NNDSS
(see Table IV-1) has been unreliable for monitoring the
incidence of newly acquired hepatitis C because many of
the cases reported do not meet the case definition for
acute disease. This has occurred because most health
departments do not have the resources required for case
investigations to determine if anti-HCV-positive labora-
tory reports received represent acute infection, chronic
infection, repeated testing of a person previously reported,
















































Figure IV-12. Estimated Incidence of Acute Hepatitis C, United States,1982-1995
Source: Sentinel Counties
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Demographic characteristics
The demographic profile of cases in 1994 and 1995 was similar to that in previous years:
 Persons 20-49 years of age accounted for >75% of cases in 1994 and 1995.
 The male:female ratio for reported cases was 1.5:1





CHARACTERISTIC No. %* No. %*
Age (Years)
<5 5 0.5 7 0.7
5-9 10 1.1 5 0.5
10-14 7 0.7 9 0.9
15-19 31 3.3 37 3.9
20-29 179 18.9 170 17.8
30-39 367 38.7 343 35.7
40-49 198 20.8 228 23.7
50-59 73 7.7 62 6.5
60+ 79 8.3 96 10.0
Sex
Male 531 56.2 569 59.2
Female 414 43.8 381 39.6
Race/Ethnicity
White, non-Hispanic 603 68.5 596 65.6
Black, non-Hispanic 156 17.7 174 19.1
Hispanic 88 10.0 94 10.3
American Indian or Alaskan Native 16 1.8 27 3.0
Asian or Pacific Islander 17 1.9 18 2.0
Table IV-8. Reported Cases of Hepatitis C/NANB by Age, Sex, and Race/Ethnicity, United States,
1994-1995
* A total of 954 and 961 cases of hepatitis C/NANB were reported to VHSP in 1994 and 1995 respectively; however, patients with
missing risk factor data are excluded here.
Source: Viral Hepatitis Surveillance Program, CDC.
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Clinical Characteristics
Hospitalization rates are higher than for hepatitis A,
and similar to rates for hepatitis B. However, hospitaliza-
tion rates for all cases of viral hepatitis reported to VHSP
are 10%-20% higher than those reported for cases in the
Sentinel Counties, suggesting that VHSP reporting may
be biased toward more severe cases. Case-fatality rates
are also slightly higher than for hepatitis A and B.










Jaundice 68.1 72.2 69.9 64.7
Hospitalized for hepatitis 32.6 23.8 28.7 39.5
Death as a result of hepatitis 2.4 0.0 2.0 3.1
1995 N=961 N=21 N=550 N=386
Jaundice 62.2 42.1 65.5 58.5
Hospitalized for hepatitis 34.2 44.4 28.5 41.9
Death as a result of hepatitis 1.9 0.0 1.2 3.0
Table IV-9. Clinical Characteristics of Patients Reported with Hepatitis C/Non-A, Non-B Hepatitis,
by Age Group, United States, 1994-1995
* A total of 954 and 961 cases of hepatitis C/NANB were reported to VHSP in 1994 and 1995 respectively; however, percentages
exclude patients with missing data for age (1% of total ), jaundice (7%-14% of total), hospitalization (6%-12% of total), and death
(6%-7% of total).
Source: Viral Hepatitis Surveillance Program, CDC.
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Risk factors
Injection drug use was the most commonly reported
risk factor among the cases for whom a risk factor was
identified, accounting for approximately one-fourth of
reported cases. Another 10% of cases are attributed to
sexual exposures including having had multiple sex part-
ners (approximately 6%) or having had sexual contact
with a person known to be infected with HCV. Although
more than half of cases in both 1994 and 1995 denied a
recognized exposure, data from the Sentinel Counties
study (see Figure IV-14) indicate that most persons iden-
tifying no specific exposure have some lifetime history of
high-risk drug or sexual behaviors.
Percentage
†
of Patients By Age (years)
1994
Total <1-14 15-39 40
N = 947 N = 22 N = 576 N = 349
Blood transfusion 3.6 6.7 2.1 5.9
Injection drug use 21.9 0.0 28.2 12.9
Employed in medical/dental field 4.9 0.0 3.5 7.5
Hemodialysis 0.5 0.0 0.0 1.4
Sexual contact of hepatitis C/NANB patient 2.4 0.0 3.5 0.9
Household contact with hepatitis C/NANB patient 1.0 4.6 1.4 0.0
Other contact with hepatitis C/NANB patient 0.7 0.0 0.7 0.9
Multiple sex partners 5.7 4.6 7.6 2.6
Unknown 59.3 84.1 53.0 67.9
1995
Total <1-14 15-39 40
N =957 N = 21 N = 550 N = 386
Blood transfusion 5.1 0.0 2.7 87.8
Injection drug use 26.4 0.0 32.2 19.3
Employed in medical/dental field 0.8 0.0 2.4 3.7
Hemodialysis 0.7 0.0 0.4 1.3
Sexual contact of hepatitis C/NANB patient 3.8 0.0 3.8 2.3
Household contact with hepatitis C/NANB patient 0.8 9.5 0.9 0.3
Other contact with hepatitis C/NANB patient 0.6 0.0 0.9 0.3
Multiple sex partners 6.4 0.0 9.3 2.1
Unknown 55.4 90.5 47.4 61.9
* Mutually exclusive groups in decreasing order of most probable cause.
†
A total of 954 and 961 cases of hepatitis C/NANB were reported to VHSP in 1994 and 1995 respectively; however, percentages
exclude patients with missing risk factor data.
Table IV-10. Epidemiologic Characteristics* of Patients Reported with Hepatitis C/Non-A, Non-B
Hepatitis, by Age Group, United States, 1994-95
Source: Viral Hepatitis Surveillance Program, CDC
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Injection drug use has remained the most commonly reported risk factor for hepatitis C/NANB, despite a
more than 55% reduction in number of cases from 1983 to 1993. Transfusion-associated cases have declined































Figure IV-13. Trends in Selected Risk Factors for Patients Reported with Hepatitis C/NANB, by
Mutually Exclusive Groups, Selected States,* 1983-1995
* Cases from 15 selected states with high reporting levels
Source: Viral Hepatitis Surveillance Program, CDC
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IV. National Surveillance for Acute Viral Hepatitis through 1995
Other High Risk (20%):
14% Drug Related
4% History of sexually transmitted disease
2% Prison






Injection Drug Use (43%)
Figure IV-14. Risk Factors Associated with Reported Cases of Acute Hepatitis C in Sentinel






Reports submitted on Form CDC 53.1 12,722 11,505
Reports submitted electronically as extended NETSS** records 7,075 10,569
Total cases reports submitted to VHSP 19,797 22,074
Total cases serologically confirmed 17,132 20,755
Total cases meeting case definition for acute hepatitis 16,937 19,905
Symptomatic hepatitis A 11,569 14,026
Symptomatic hepatitis B 4,242 4,715
Hepatitis A and B co-infection 172 203
Symptomatic C/non-A, non-B hepatitis 954 961
Total cases reported to NNDSS* 47,227 46,963
Hepatitis A 29,796 31,582
Hepatitis B 12,517 10,805
Hepatitis C/non-A, non-B 4,470 4,576
Hepatitis, unspecified 444
†
* National Notifiable Diseases Surveillance System
**National Electronic Telecommunications System for Surveillance
†
No longer reported as of 1995
Table IV-11. Cases Reported to Viral Hepatitis Surveillance Program Compared with NNDSS, by
Type of Submission, 1994-1995
81% - 100% 61% - 80% 41% - 60% 21% - 40% 0% - 20%
Arkansas Alabama Florida Arizona Alaska
Kansas Connecticut Iowa Colorado California
Maryland District of Columbia Michigan Georgia Idaho
Montana Delaware Minnesota Hawaii Kentucky
Oklahoma Illinois Missouri South Carolina Mississippi
Rhode Island Indiana North Carolina Tennessee New Jersey
South Dakota Louisiana North Dakota Wyoming New York City
Utah Maine Nebraska Oregon
Vermont Massachusetts Nevada Texas
New Hampshire New Mexico






*and other reporting areas: New York City and the District of Columbia




Epidemiologic data about reported cases of
acute viral hepatitis are essential for defining the
groups at risk and for monitoring changes in such
groups. Since new disease acquisition is the
event of interest, chronic infections should not be
reported.
In 1990 the VHSP updated the case definition
for acute viral hepatitis to include IgM antibody
to hepatitis B core antigen (IgM anti-HBc) for
improved diagnosis of acute hepatitis B, to clarify
the reporting of NANB hepatitis, and to include
delta hepatitis as a separate diagnostic category.
The clinical criteria remain the same: an acute
case must include an illness with a discrete date
of onset, and jaundice or elevated serum
aminotransferase levels greater than 2.5 times the
upper limit of normal. The serologic criteria used
to distinguish the different types of hepatitis were
as follows: hepatitis A is defined as being positive
for IgM antibody to hepatitis A virus (IgM
anti-HAV-positive); hepatitis B as positive for
IgM anti-HBc-positive (if done) or hepatitis B
virus surface antigen(HBsAg) and negative for
IgM anti-HAV (if done); and NANB hepatitis as
negative for IgM anti-HAV, and also for IgM
anti-HBc (if done) or HBsAg-negative. In
1994-95, 94% of cases had sufficient serologic test-
ing to designate a specific type. Only those
patients with a specific serologic diagnosis were
included in these analyses.
Cases were excluded if they do not satisfy the
criteria for acute viral hepatitis. Among
serologically confirmed cases in 1994-95, 5% of
hepatitis A cases, 11% of hepatitis B cases, and 7%
of NANB hepatitis cases were excluded because
they failed to meet the clinical case criteria.
Compared with hepatitis B patients who fulfilled
the criteria for acute hepatitis, more persons with
hepatitis B who were asymptomatic or had no
date of onset were ≤14 years of age, were
Asian/Pacific Islander, were dialysis patients, or
had histories of blood transfusions or surgery.
Except for age, NANB hepatitis patients not
meeting the case definition showed a similar
pattern. Compared with NANB hepatitis
patients who fulfilled the criteria for acute hepati-
tis, more persons with NANB hepatitis who were
asymptomatic or had no date of onset were ≥40
years of age, were patients undergoing dialysis,
or had histories of surgery. This pattern, as well
as that for hepatitis B, is consistent with that for
the earlier years. For both hepatitis B and NANB
hepatitis, these findings suggest that these
persons may have been routinely screened for
HBsAg or for antibody to the hepatitis C virus
(anti-HCV), and found to be positive without any
evidence of acute illness.
Hepatitis A and B coinfections were examined
in the 1995 data, and constituted approximately
1% of cases meeting the case definition. These
cases displayed no specific clustering or associa-
tions with geographic or demographic factors.
For purposes of risk factor analysis, these cases
were counted twice, and were included as hepati-
tis A cases and hepatitis B cases.
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Appendix: State and Territorial Epidemiologists and
Laboratory Directors
State and Territorial Epidemiologists and Laboratory Directors are acknowledged for their
contributions to hepatitis surveillance programs.. The epidemiologists and laboratory direc-
tors listed below were in the positions shown as of October 1996.
State/Territory Epidemiologist Laboratory Director
Alabama John P. Lofgren, MD William J. Callan, PhD
Alaska John P. Middaugh, MD Gregory V. Hayes
Arizona Robert W. England, Jr. MD, MPH Barbara J. Erickson, PhD
Arkansas Thomas C. McChesney, DVM Michael G. Foreman
California Stephen H. Waterman, MD, MPH Michael G. Volz, PhD
Colorado Richard E. Hoffman, MD, MPH Ronald L. Cada, DrPH
Connecticut James L. Hadler, MD, MPH Sanders F. Hawkins, PhD
Delaware A. LeRoy Hathcock, PhD Mahadeo P. Verma, PhD
District of Columbia Martin E. Levy, MD, MPH James B. Thomas, ScD
Florida Richard S. Hopkins, MD, MSPH E. Charles Hartwig, ScD
Georgia Kathleen E. Toomey, MD, MPH Elizabeth A. Franko, DrPH
Hawaii Richard L. Vogt, MD Vernon K. Miyamoto, PhD
Idaho Jesse F. Greenblatt, MD, MPH Richard H. Hudson, PhD
Illinois Byron J. Francis, MD, MPH David F. Carpenter, PhD
Indiana Gregory K. Steele, MD, PhD David E. Nauth (Acting)
lowa M. Patricia Quinlisk, MD, MPH Mary J. R. Gilchristr, PhD
Kansas Gianfranco Pezzino, MD, MPH Roger H. Carlson, PhD
Kentucky Reginald Finger, MD, MPH Thomas E. Maxson, DrPH
Louisiana Louise McFarland, DrPH Henry B. Bradford, Jr, PhD
Maine Kathleen F. Gensheimer, MD, MPH John A. Krueger (Acting)
Maryland Diane M. Dwyer, MD J. Mehsen Joseph, PhD
Massachusetts Alfred DeMaria, Jr, MD Ralph J. Timperi, MPH
Michigan Kenneth R. Wilcox, Jr, MD, DrPH Robert Martin, DrPH
Minnesota Michael T. Osterholm, PhD, MPH Pauline Bouchard, JD, MPH
Mississippi Mary Currier, MD, MPH Joe O. Graves, PhD
Missouri H. Denny Donnell, Jr, MD, MPH Eric C. Blank, DrPH
Montana Todd D. Damrow, PhD, MPH Douglas O. Abbott, PhD
Nebraska Thomas J. Safranek, MD John D. Blosser
Nevada Randall L. Todd, DrPH Arthur F. DiSalvo, MD
New Hampshire Vacant Veronica C. Malmberg, MSN
New Jersey Lyn Finelli, DrPh (Acting) Thomas J. Domenico, PhD (Acting)
New Mexico C. Mack Sewell, DrPH, MS Loris W. Hughes, PhD
New York City Benjamin A. Mojica, MD, MPH Stanley Reimer
New York State Dale L. Morse, MD, MS Ann Wiley, PhD
North Carolina J. Michael Moser, MD, MPH Lou F. Turner, DrPH
North Dakota Larry A. Shireley, MS, MPH James D. Anders, MPH
Ohio Thomas J. Halpin, MD, MPH Kathleen L. Meckstroth, DrPH
Oklahoma J. Michael Crutcher, MD, MPH (Acting) Garry L. McKee, PhD
Oregon David Fleming, MD Michael R. Skeels, PhD, MPH
Pennsylvania James T. Rankin, Jr, DVM, PhD, MPH Bruce Kieger, DrPH
Rhode Island Utpala Bandy, MD, MPH Walter Combs, PhD
South Carolina James J. Gibson, MD, MPH Harold Dowda, PhD
South Dakota Susan E Lance, DVM, MPH Richard S. Steece, PhD
Tennessee William L. Moore, MD Michael W. Kimberly, DrPH
Texas Diane M. Simpson, MD, PhD David L. Maserang, PhD
Utah Craig R. Nichols, MPA Charles D. Brokopp, DrPH
Vermont Vacant Burton W. Wilcke, Jr, PhD
Virginia Grayson B. Miller, Jr, MD James L. Pearson, DrPH
Washington Paul Stehr-Green, DrPH, MPH Jon M. Counts, DrPH
West Virginia Loretta E. Haddy, MA, MS Frank W. Lambert, Jr, DrPH
Wisconsin Jeffrey P. Davis, MD Ronald H. Laessig, PhD
Wyoming Gayle L. Miller, DVM, MPH Roy J. Almeida, DrPH
American Samoa Edgar C. Reid, MO, DSM, MPH —
Federated States of Micronesia Vacant —
Guam Robert L. Haddock, DVM, MPH Florencia Nocon (Acting)
Marshall Islands Tom D. Kijner —
Northern Mariana Islands Jose L. Chong, MD Isamu J. Abraham, DrPH
Palau Jill McCready, MS, MPH —
Puerto Rico Carmen C. Deseda, MD, MPH Jose Luis Miranda Arroyo, MD
Virgin Islands Donna M. Green, MD Norbert Mantor, P
